Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Aug 8, 2026, 13:56Cameron Horner: Whole Blood in Prehospital Care – What Does the Best Evidence Tell Us?
-
Aug 8, 2026, 13:52Carl Allen: New AAP Guidance Updates Pediatric Iron Deficiency Screening and Treatment
-
Aug 8, 2026, 13:39Augustina Isioma Ikusemoro: Platelet Inventory – The Most Unpredictable Balancing Act in Healthcare
-
Aug 8, 2026, 13:38João Gorgulho: Liquid Biopsy for Precision Immunotherapy in Hepatocellular Carcinoma
-
Aug 8, 2026, 13:33Emeka Patrick Chukwuka: Treatment Sequencing After JAK Inhibitor Failure in Relapsed and Refractory Myelofibrosis
-
Aug 8, 2026, 13:20Jhalak Patel: A Proud Milestone in Blood Banking and Transfusion Medicine
-
Aug 8, 2026, 09:56Same Drug, Different Results – ESC Working Group on Cardiovascular Pharmacotherapy
-
Aug 8, 2026, 09:37Maxime Dely: Behind Every Machine, There Is a Human Story
-
Aug 8, 2026, 09:30Veronica Sanchez: What You Need to Know About CKM Syndrome